sellWeak10b5-1 plan
Mark J Gergen sold $278k of PSTX
Executive Chairman at Poseida Therapeutics, Inc.. 30,000 shares at an average of $9.27, traded Nov 26, 2024, filed Nov 27, 2024.
Warning score
0Value
$278k
30,000 shares
Holdings after
651,291
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleChair
- +14Trade size$278k at market
- 0Share of holdings soldSold 4.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-131665, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2024 | MOption exercise Common Stock10b5-1 | +30,000 | $2.78 | $83k | 681,291 | Nov 27, 2024 |
| Nov 26, 2024 | SOpen-market sale Common Stock10b5-1 | -30,000 | $9.27 | $278k | 651,291 | Nov 27, 2024 |
| Nov 26, 2024 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -30,000 | $0.00 | $0 | 126,372 | Nov 27, 2024 |
Related signals
Other insiders at Poseida Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Poseida Therapeutics, Inc. | Mark J Gergen Executive Chairman | $284k 30,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.